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Abstract 
Background 
Transgenic expression of human complement regulatory proteins (hCRPs) reduces the frequency of 
hyperacute rejection (HAR) in Gal-positive cardiac xenotransplantation. In this study we examine 
the impact of human CD55 (hCD55) expression on a Gal knock-out (GTKO) background using pig-
to-primate heterotopic cardiac xenotransplantation. 
Methods 
Cardiac xenotransplantation was performed with GTKO (Group 1; n=6) and GTKO.hCD55 (Group 
2; n=5) donor pigs using similar immunosuppression. Cardiac biopsies were obtained 30 minutes 
after organ reperfusion. Rejection was characterized by histology and immunohistology. Intragraft 
gene expression, serum non-Gal antibody and antibody recovered from rejected hearts were 
analyzed. 
Results 
HAR of a GTKO heart was observed. Remaining grafts developed delayed xenograft rejection. 
Median survival was 21 and 28 days for Groups 1 and 2 respectively. Vascular antibody deposition 
was uniformly detected 30 minutes after organ reperfusion and at explant. A higher frequency of 
vascular C5b deposition was seen in GTKO organs at explant. Serum non-Gal antibody, antibody 
recovered from the graft and intragraft gene expression were similar between the groups. 
Conclusion 
HAR of GTKO hearts without hCD55 may occur. Expression of hCD55 appeared to restrict local 
complement activation, but did not improve graft survival. Chronic vascular antibody deposition 
with evidence of protracted endothelial cell activation was seen. These observations suggest that 
non-Gal antibody-induced chronic endothelial cell activation coupled to possible haemostatic 
incompatibilities may be the primary stimulus for DXR of GTKO hearts. To avoid possible HAR, 
future clinical studies should employ donors expressing hCRPs in the GTKO background. 
Keywords: Cardiac xenotransplantation, complement regulation, endothelial cell activation, 
antibody-mediated rejection, Xenotransplantation 
Introduction 
In the pig to nonhuman primate model, solid organ xenograft survival is limited by hyperacute 
(HAR) and delayed xenograft rejection (DXR). Both of these rejection mechanisms are antibody-
mediated processes which induce organ rejection through a combination of complement mediated 
injury and antibody induced endothelial cell (EC) activation.(1) Disparities in porcine and primate 
haemostatic regulation may also contribute to DXR.(2) HAR is characterized by vascular antibody 
and complement deposition with widespread hemorrhage and thrombosis within the xenograft. 
Genetic modification of the donor, can alleviate HAR. Transgenic expression of human 
complement regulatory proteins (hCRPs: CD46, CD55 or CD59) enhances the xenograft’s intrinsic 
resistance to complement mediated injury (3, 4) and mutation of the α-galactosyl transferase gene 
(GTKO) eliminates galactose α 1,3, galactose (αGal) the major xeno-antigen.(5) 
Transgenic hearts expressing hCRPs generally blocked HAR and extend graft survival to 3 - 7 days 
in the absence of immunosuppression.(6) This was not a perfect solution however as there were 
several reported instances where HAR despite hCRP expression.(7, 8) Elimination of the αGal 
antigen likewise blocks HAR although experience with GTKO transplants remains relatively 
limited. The initial cardiac transplants using GTKO organs reported no evidence of HAR.(9) This 
was not surprising given that the recipients were selected for minimal presence of non-Gal 
preformed antibody and most recipients were treated with cobra venom factor. In contrast, using 
recipients with preformed non-Gal IgM, we have reported a case of HAR after heterotopic cardiac 
xenotransplantation of a GTKO heart (10) and we and others have noted early antibody-mediated 
graft injury with complement deposition.(11, 12) These results suggest, at least in the nonhuman 
primate model, that the level of preformed non-Gal antibodies in the recipient and the expression of 
non-Gal antigens in the donor are sufficient to initiate early antibody-mediated injury which may 
affect GTKO xenograft survival. 
When HAR is blocked, organs are rejected by delayed xenograft rejection (DXR). Despite the large 
reduction in immunogenicity achieved using GTKO donors, the immunopathology of DXR for both 
Gal-positive hCRP transgenic and GTKO donor organs is similar showing early vascular antibody 
deposition and myocyte vacuolization, with later microvascular thrombosis, and coagulative 
necrosis.(13) Vascular deposition of complement products is reported at explant for GTKO cardiac 
xenografts despite the use of cobra venom factor.(9, 14) Vascular complement deposition is 
variably observed in hCRP transgenic organs where complement restriction at the cell surface may 
be more efficient than systemic complement depletion.(9, 15-17) Expression of hCRP transgenes 
can extend xenograft survival compared to wild type organs however these transgenes do not block 
an induced antibody response and do not block DXR. 
The effects of hCRP expression on DXR in the GTKO background has not been investigated. While 
expression of hCRPs is generally assumed to be beneficial there remains considerable debate on the 
relative contribution to DXR of complement mediated EC injury, antibody-mediated endothelial 
activation, and disparities in haemostatic regulation. These three processes are not completely 
distinct, as sublytic complement activation can exacerbate EC activation and anaphylatoxin release 
can attenuate innate immune responses, however, expression of hCRPs is expected to primarily 
limit vascular complement-mediated injury. Likewise, local vascular regulation of complement 
amplification does not directly address disparities in haemostatic regulation such as porcine 
thrombomodulin. In this study we use heterotopic pig-to-primate cardiac xenotransplantation to 
compare the immunohistology and graft survival of GTKO and GTKO:CD55 donor organs. The 
study groups were matched for immunosuppressive treatments and all recipients had preformed 
non-Gal reactive antibody prior to transplant. 
Results 
Transgenic pigs and transplant survival 
Gal-deficient pigs expressing CD55 (GTKO.hCD55) were produced by standard breeding 
procedures starting with GT
+/-
 females (18) and incorporating a murine H2K regulated hCD55 
transgene. Intercrosses were performed to achieve GT-/- homozygosity. GTKO.hCD55 animals 
show no evidence of Gal expression in the heart. (Figure 1A) Expression of hCD55 is evident on 
primary cultured aortic ECs and on microvascular ECs in the heart. (Figure 1B and C) This line of 
pigs shows consistent expression of CD55 in heart RNA. (Figure 1D) 
 
Figure 1 
GTKO.CD55 donor characteristics and graft survival 
This study used a modified immunosuppressive regime consisting of induction therapy coupled to a 
moderate level of Tacrolimus and Sirolimus maintenance. The levels of Tacrolimus and Sirolimus 
were similar to those used previously which reliably resulted in cardiac xenograft survival of 4 - 8 
weeks.(15, 16) These transplant groups were well matched.(Table 1) All recipients showed anti-pig 
non-Gal IgM and cytotoxicity to GTKO porcine aortic endothelial cells (PAECs) prior to transplant. 
Minimal non-Gal IgG was present prior to transplant except in two GTKO recipients explanted on 
days 2 and 22. Although levels of pretransplant antibody and cytotoxicity varied between 
individuals there was no significant difference between the two groups (IgM, p = 0.48; IgG, p = 
0.13; cytotoxicity p = 0.25) There was no significant difference in serum Tacrolimus (p=0.78) or 
Sirolimus (p=0.71) levels between the groups. Donor age (p = 0.42) and donor and recipient weight 
were not significantly different (p = 0.40 for both donor and recipient weight). Transplant survival 
ranged from 0 to 128 in Group 1 and 15 to 52 in Group 2. In both groups one recipient died from 
hemorrhage after a vascular rupture on day 2 (Group 1) and after rupture of the left atrial appendage 
on day 15 (Group 2). All other grafts were rejected or showed significant loss of contractility at the 
time of explant. There was not a significant difference in median Kaplan-Meier survival of 22 and 
28 days for Groups 1 and 2 respectively (Figure 1E). Pretransplant serum IgM levels and serum 
cytotoxicity were strongly correlated (linear regression R = 0.82) but no strong relationship was 
observed between pretransplant antibody levels or cytotoxicity and graft survival (data not shown). 
 
Table 1 
Comparison of Transplant Group Characteristics. 
Xenograft rejection 
There was no postoperative anticoagulation in these recipients and no evidence of perioperative 
consumptive coagulopathy. Both groups maintained postoperative circulating platelet counts greater 
than 100 × 10
9
 /liter (data not shown). Only one recipient in Group 2 showed a reduction of 
platelets immediately after transplant. In this recipient platelets decreased to 103 ×10
9
/liter from 
258 prior to transplant. Platelet levels rebounded however to 312 ×109/liter on postoperative day 5. 
Hyperacute rejection was observed in one Group 1 recipient (Table 1, Figure 2A-C). A biopsy 
obtained 30 minutes after reperfusion showed normal myocardial histology, extensive vascular IgM 
deposition and moderate focal deposition of C5b (insert Figure 2A-C). Over a period of 90 minutes 
post transplant the heart became progressively discolored and dyskinetic leading to asystole. 
Histology at that time showed extensive intramyocardial hemorrhage, with vascular IgM deposition 
and increased levels of C5b deposition (Figure 2A-C). Pre transplant serum from this recipient did 
not have an unusually high degree of complement mediated cytotoxicity to GTKO PAECs (Table 
1). 
 
Figure 2 
Histology and immunohistology of cardiac xenografts 
Excluding the HAR in Group 1, delayed xenograft rejection (DXR) was the cause of graft failure. 
All grafts showed vascular antibody staining 30 minutes after reperfusion (inserts Figures 2E and 
2H) with C5b deposition detected only in the GTKO graft that was hyperacutely rejected and 
transiently in a GTKO:CD55 graft that rejected on day 28. (Table 2). At explant all samples 
continued to showed vascular IgM staining (Figure 2E and 2H) and most showed IgG binding (data 
not shown). There was variable C5b deposition at explant (Figure 2F and I) as donor hearts 
expressing hCD55 showed a lower frequency of C5b deposition and appeared to effectively restrict 
complement activation. Steady state vascular C5b deposition was present in only one Group 2 heart 
(20%) which rejected on day 41. (Table 2). In contrast, Group 1 explanted GTKO hearts showed a 
higher frequency (80%) of vascular C5b staining (Table 2). 
 
Table 2 
Summary of Immunohistochemical Stains. 
Immune response and intragraft gene expression 
DXR was accompanied by an increased level of serum non-Gal antibody (Table 1, Figure 3A and 
B). Increases in non-Gal IgM ranged from minimal (< 2-fold) up to a 9-fold and induction of non-
Gal IgG ranged from minimal up to 8 fold. Consistent with an induced antibody response non-Gal 
antibody was also recovered from explanted tissues. The qualitative recovery of non-Gal antibody 
reactivity from explanted tissue generally reflected the level of induced serum non-Gal antibody 
(Table 1). 
 
Figure 3 
Immune response and endothelial cell activation 
Analysis of intragraft gene expression indicates EC activation in all grafts as evidenced by 
increased expression of CD54 and CD106 (Figure 3C). Elevated levels of CD54 and CD106 
expression were not apparent in the GTKO graft after HAR but were evident on days 2 and 15 in 
the two grafts that did not reject. The early increase in CD54 and CD106 expression in these grafts 
prior to rejection suggests an ongoing state of EC activation. 
Discussion 
There have been numerous reports of cardiac xenotransplantation using various hCRP donors under 
a variety of conditions. While interpretation of this literature might imply that inclusion of an hCRP 
transgene in the GTKO background would be beneficial, there has been to our knowledge no direct 
study of this question. Our study compared two carefully matched transplant groups and shows that 
in the absence of CD55, nonhuman primates with preformed non-Gal IgM may induce HAR of 
GTKO cardiac xenografts. HAR of the GTKO heart displayed the classic markers of HAR observed 
for wild type organs namely prominent vascular deposition of antibody and complement, 
accompanied by rapid loss of contractility and notable intravascular hemorrhage (Figure 2A - C). 
Detection of a HAR for a GTKO heart is consistent with the early antibody-mediated injury, and 
limited GTKO graft survival reported by Ezzelarab et al.(11) Our recipients showed pre transplant 
cytoxicity to GTKO PAECs and 50% of human and baboon sera has been reported to be lytic for 
GTKO porcine cells. (19) Our study underscores the importance of utilizing nonhuman primate 
recipients with preformed non-Gal antibody when assessing the efficacy of new transgenic or 
therapeutic treatments. This study is not sufficiently powered to estimate an overall frequency of 
HAR for GTKO hearts or the efficacy of CD55 expression to prevent HAR. The variables that may 
contribute to HAR, preformed non-Gal antibody titers, specificity, and antigen density are poorly 
understood, making it difficult to predict the occurrence of HAR in individual recipients. We 
suspect, based on the generally lower titer of non-Gal IgM compared to anti-Gal IgM, that the 
frequency of HAR for GTKO hearts, at least in nonhuman primates, will be relatively rare. Our 
study also can not address the potential impact of antibody directed to sialic acid N-
glycolylneuraminic acid (Neu5Gc) antigens since baboons do not make this antibody specificity. In 
humans anti-Neu5GC is present, and may constitutes 7 -13% of the preformed non-Gal human 
antibody repertoire.(20) The potential of anti-Neu5GC to affect HAR or DXR is controversial but 
the presence of an additional preformed non-Gal antibody specificity in humans, compared to 
nonhuman primates, seems unlikely to diminish the potential for early antibody-mediated graft 
injury. Since any future clinical application of cardiac xenotransplantation must, at the very least, be 
as free as possible from the risk of HAR, these observations suggest that expression of at least one 
hCRP in the GTKO background will minimally be required for this purpose. 
This study demonstrates that expression of hCD55 in the GTKO background limited the steady 
state vascular deposition of C5b at the time of rejection but did not extend GTKO xenograft 
survival. This suggests that the mechanism(s) of DXR, under conditions where vascular antibody 
deposition and a mild induced non-Gal antibody response is detected, may not be dependent on 
complement-mediated EC injury per se but likely result from processes, such as chronic EC 
activation or incompatibilities in thromboregulation which would not necessarily be directly 
affected by vascular hCRP expression. We note that under different immunosuppressive regimens, 
where evidence of cellular and humoral sensitization may be minimal, DXR with vascular antibody 
deposition, widespread microvascular thrombosis, and coagulative necrosis still occurs.(21) This 
suggests that DXR of cardiac xenografts may result more from the effects of vascular EC activation, 
possibly coupled to disparities in thromboregulation, than the result of direct complement-induced 
cell injury. Consistent with this interpretation we detected increased expression of mRNA encoding 
EC adhesion proteins CD54 and CD106. Increased expression of these genes, evident as early as 2 
days post transplantation, is indicative of EC activation. This observation, and the detection of 
vascular antibody deposition 30 minutes after reperfusion, strongly suggests a chronic state of EC 
activation, probably resultant to binding of non-Gal antibody, prior to the histological changes of 
DXR and organ rejection. This interpretation is consistent with our recent observation of changes in 
porcine gene expression after orthotopic cardiac xenotransplantation where, in the absence of graft 
rejection, cardiac gene expression, indicative of EC activation, was detected 2 to 57 days post 
transplant.(22) Given the reported specificity of induced non-gal antibody,(10, 12) with a potential 
to directly affect key EC inflammatory and thromboregulatory functions, and the observation of 
differential changes in EC gene expression in response to anti-Gal and non-Gal antibody (23) the 
response of vascular EC to chronic antibody binding may be complex, resulting in physiological 
changes which simultaneously promote and prevent EC injury and thrombosis. Haemostatic 
regulatory incompatibilities may eventually tip this balance resulting in microvascular thrombosis. 
If this is the case then immunosuppressive strategies which do not eliminate synthesis of preformed 
antibody may not be effective over the long term in preventing DXR. Investigation on the relative 
contribution of incompatibilities in haemostatic regulation and chronic EC activation to DXR awaits 
the development and availability of pigs expressing transgenes to regulate coagulation. 
This study provides the first direct comparison of the effects of hCRP expression in GTKO cardiac 
xenotransplantation. Our observations show that hCD55 expression contributes to the prevention of 
HAR, restricts vascular complement activation within the graft, but does not extend overall graft 
survival. The results are consistent with the hypothesis that DXR of GTKO organs may include 
multiple mechanisms which are not strictly complement dependent, and further suggest that 
blocking of preformed nonhuman primate non-Gal antibody is needed not only to insure the 
absence of HAR but also to prevent chronic EC activation and DXR. Since future clinical studies 
would minimally require freedom from HAR, we suggest that it is important to incorporate at least 
one hCRP function in the donor organ in any proposed clinical studies. 
Materials and Methods 
Heterotopic Heart Transplantation 
All transplants utilized the pig-to-baboon heterotopic abdominal cardiac xenograft model and were 
in compliance with standards established by the Institutional Animal Care and Use Committee of 
the Mayo Clinic and Foundation and consistent with the Guide for the Care and Use of Laboratory 
Animals prepared by the Institute of Laboratory Animal Resources and published by the National 
Institutes of Health (NIH publication No. 86-23, revised 1996). Group 1 recipients (n=6) received 
Gal-deficient (GTKO) hearts, Group 2 (n=5) recipients received GTKO hearts expressing the 
human CD55 (hCD55) complement regulatory protein (GTKO.hCD55). A preliminary description 
of survival for group 1 recipients was previously described.(10) Immunosuppression was the same 
in each group consisting of induction therapy on postoperative days (POD) 1-5 with antithymocyte 
globulin (ATG), 1.5 mg/kg on postoperative days 1 - 5 and on POD -7, 0,7 and 14 with Rituximab 
(17 mg/kg). Maintenance immunosuppression consisted of Tacrolimus (target levels 10-20 ng/ml) 
and Sirolimus (target levels 5-15 ng/ml). A steroid taper and prophylactic antibiotics and antiviral 
treatments were also given. No postoperative anticoagulation therapy was used. Xenograft 
contractility was measured at 2-3 day intervals by echocardiography and manual palpation. 
Palpation was scored from 0, no contractility to 6, maximal contractility. At rejection, defined by an 
absence of contractility, xenografts were explanted and surviving recipients were maintained on 
immunosuppression for at least 20 days. 
Histology 
Apical left ventricular (LV) biopsies were taken 30 minutes after reperfusion. At explant full 
thickness mid-ventricular sections of right (RV) and LV were collected. Standard hematoxylin and 
eosin stained sections were made for all samples. Immunohistochemistry (IHC) samples were 
frozen and sections were stained to detect vascular IgM (A0425, DAKO, Carpinteria, CA), IgG 
(A0423, DAKO), and C5b (RDI Concord, MA, clone HCC5b.1), using the DUAL+/HRP labeled 
polymer (K4061, DAKO, Carpinteria, CA) and Vector Nova Red (IgM), or 3,3’-diaminobenzidine 
(C5b). IHC slides were counterstained with modified Schmidt’s hematoxylin. Staining was assessed 
for intensity (0, none; 1, minimal; 2, easily recognized, characterized by smooth linear decoration of 
endothelial cells (ECs); and 3, intense, granular staining of ECs) and the extent of reactivity (focal: 
<25 % of vessels; or diffuse: ≥25 % of vessels). 
Intragraft gene expression 
Intragraft gene expression was measured by qualitative RT-PCR using total RNA from left ventricle 
samples obtained at explant. Gene expression was assessed using 0.5 micrograms of RNA and 
primers for porcine adhesion proteins CD54 (forward: GGCTTGGAGGTGCTGAAATCTC, 
reverse: TGGCTGGCAGGACATAAGTTTG), CD106 (forward: 
ATACTTTGGATGGTGTTTGCCG, reverse: AACTGGGTCCTTGGGTGAGATG) and porcine β-
actin (forward: AAGATCAAGATCATCGCGCCTCCA, reverse: 
ACTCCTGCTTGCTGATCCACATCT). Gene specific amplification was performed in a MyCycler 
Thermal Cycler (Bio-Rad, Hercules, CA) using one-step RT-PCR reaction (USB-Affymetrix, Santa 
Clara, CA) with reverse transcription performed at 42°C for 30 minutes. Amplification products 
were run in a 1.5% agarose gel. 
Detection of Non-Gal antibody 
Induced non-Gal antibody was detected by flow cytometry from serial serum dilutions (1:10 – 1:80 
dilutions) to measure IgM and IgG binding to primary GTKO porcine aortic ECs. Antibody binding 
was detected using goat anti-Human IgG-FITC (Zymed Laboratories, San Francisco, CA) or goat 
anti-human IgM-FITC (Invitrogen, Life Technologies Corp. Carlsbad, CA). All flow cytometry was 
performed using a FACScalibur cytometer and Cellquest software (BD Pharmingen, San Diego, 
CA). The fold increase in antibody binding was calculated as the ratio of mean fluorescence in 
postoperative and pretransplant serum. Antibody bound to explanted tissue antibody was recovered 
as previously described.(16) The amount of IgG and IgM in the eluted material was determined by 
ELISA (Bethyl labs). Dilutions of recovered materials (50, 25 and 12.5%) were tested for non-Gal 
antibody using flow cytometry as described. Recovered non-Gal antibody reactivity was scored 
qualitatively with mean fluorescent antibody binding intensity less than 1.5-fold above background 
scored as negative, intensities between 1.5 and 2.5 scored +1, between 2.5 and 3.5 fold scored +2, 
and greater than 3.5 fold scored as +3. Background was set using only the secondary reagents. 
Statistics 
The comparison of immunosuppressive drug levels, donor age, and donor and recipient weights was 
performed using a Student’s t-test. P-values < 0.05 were considered statistically significant. 
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